Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-10726 · 1 trial · 4 indications
Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.
Incidence of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Escalating doses of CTX-10726 |
| Dose Expansion Cohort 2 | EXPERIMENTAL | Dose of CTX-10726 depending on Cohort 1 data |
| Name | Type | Description |
|---|---|---|
| CTX-10726 | DRUG | Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks. |
Inclusion Criteria: 1. Age 18 years or older. 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including: 2a: R...
CTX-10726 is an investigational small molecule being developed for the treatment of gastroesophageal cancer (GC). It is currently in Phase 1 clinical development and is also being studied in other solid tumors including hepatocellular carcinoma, endometrial cancer, and renal cell carcinoma.
CTX-10726 targets PD-1, a protein involved in immune checkpoint regulation. By targeting PD-1, the drug is designed to modulate the immune system's response to cancer cells. It is being evaluated as a potential treatment for gastroesophageal cancer and other solid tumors.
CTX-10726 is being developed by Compass Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol CMPX. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
CTX-10726 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the drug's safety and tolerability in patients with certain types of cancer.
CTX-10726 is being studied in a Phase 1 clinical trial registered as NCT07419841. This trial is titled 'A Phase 1 Study of the Safety and Tolerability of CTX-10726' and is currently recruiting participants in the United States. The trial is enrolling approximately 70 patients with gastroesophageal cancer, hepatocellular carcinoma, endometrial cancer, or renal cell carcinoma.
CTX-10726 is the investigational name for this drug candidate. No alternative names have been disclosed for this compound. It is being developed by Compass Therapeutics and is currently in Phase 1 clinical trials for the treatment of gastroesophageal cancer and other solid tumors.